Global Cancer Immunotherapy Market Set To Grow To $106.6bn By 2022

06 August 2018
Pharma

Visiongain has launched a new pharma report Cancer Immunotherapy Market Report : Monoclonal Antibodies, Cytokines & Immunomodulators, Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy, Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer

The future of the cancer immunotherapy market looks promising, as a number of new and innovative therapies are coming on to the market. Monoclonal antibodies (mAbs) held the largest market share. Monoclonal antibodies have gained significant attention in recent years due to their target specificity, high efficacy and less toxicity. Due to the success of immunotherapeutics in curing cancer, research companies are now focused on the development of immunotherapeutics for cancer treatments. Demand for personalized medicine is owing to the growth of therapeutic antibodies.

The lead analyst of the report commented - “The global cancer immunotherapy market will see strong growth over the forecast period. The approval of advance therapeutics is paradigm shifting in the field from conventional chemotherapies to immunotherapies. Increased R&D funding coupled with rising prevalence of cancer and continued commitment by government bodies and healthcare providers will propel demand and accentuate growth in the market. However, challenges in clinical trials, high costs and changes in reimbursement policies will restrain the market.
Asia Pacific is expected to experience the fastest growth as more multinational companies such as AstraZeneca, Merck and Co. and Pfizer invest in the region through mergers and acquisitions to retain their market share and thus diversify their product portfolio.’’

Leading companies featured in the report include Roche AstraZeneca, Merck & Co., Novartis, Adaxis Inc, Bristol-Myers Squibb (BMS), Bayer AG, Roche, Eli Lilly and Co. and Medtronic Plc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever